Ziosk's Howard on Lifting Sales, Ops Via Digital
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
U.S. Robo Taxi Market Analysis Report 2025-2030, with Profiles of Waymo, Cruise, Tesla, Aptiv, Uber Technologies, Lyft, Zoox, Aurora Operations, Nuro, and Gatik
Explore the booming U.S. Robo Taxi Market, projected to grow at a 74.6% CAGR from 2025-2030. Fueled by urban policies and innovation from tech giants like Waymo and Uber, the market thrives on autonomy and affordability. Discover trends in the latest report on market growth, competitive strategies, and more. Dublin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The "U.S. Robo Taxi Market Size, Share & Trends Analysis Report By Propulsion Type, By Component Type, By Level Of Autonomy, By Vehicle Type, By Service Type, By Application, And Segment Forecasts, 2025 - 2030" report has been added to U.S. robo taxi market size was estimated at USD 0.45 billion in 2024 and is projected to grow at a CAGR of 74.6% from 2025 to 2030. The growth of the U.S. robo-taxi industry is driven by progressive urban policy initiatives in major metropolitan areas such as San Francisco, Los Angeles, Austin, and Phoenix. These cities are at the forefront of smart transportation experimentation, with municipal authorities actively piloting autonomous mobility zones, congestion pricing models, and AV-specific zoning codes. City governments are also forging direct partnerships with mobility tech firms to co-develop operational frameworks that align with local sustainability and traffic management goals. This decentralized, city-driven approach to AV adoption is unique to the U.S. and is accelerating the commercial rollout of robo-taxi services in high-density urban many other countries, the U.S. robo taxi market benefits from a hyper-competitive innovation ecosystem fueled by well-funded technology giants and a vibrant startup culture. Companies such as Waymo, Cruise, Zoox (Amazon), and Aurora leverage significant capital, proprietary technology stacks, and local testing permissions to rapidly iterate and refine autonomous ride-hailing platforms. At the same time, smaller startups are carving out niche innovations in mapping, safety software, and autonomous fleet management. The high concentration of intellectual property, venture funding, and talent in U.S. tech hubs, particularly in California and Texas, ensures a continuous stream of innovation that propels the robo-taxi market the U.S., established ride-hailing giants like Uber and Lyft are strategically positioning themselves to incorporate robo-taxis into their platforms, either through in-house development or partnerships with AV companies. This integration enables a seamless user experience and facilitates the transition for current ride-hail customers. Additionally, new business models such as robo-taxi subscriptions and bundled mobility packages are being tested in select U.S. markets. These models offer flat-rate or usage-based pricing, ensuring predictability and affordability for urban commuters and signaling a shift from per-ride charges to service-based market dynamics serve as a unique catalyst for robo-taxi adoption in the U.S. A persistent shortage of rideshare and taxi drivers, coupled with rising wages and employment regulations in states like California and New York, is propelling fleet operators and mobility companies to hasten the transition toward automation. Robo-taxis offer an appealing alternative by removing driver-related operational costs and compliance complexities. This labor-focused cost pressure is particularly noticeable in urban centers with high demand for 24/7 mobility services, where the cost-effectiveness of driverless fleets provides significant margin U.S. insurance industry plays a pivotal role in enabling robo-taxi deployments by developing innovative underwriting models and liability frameworks tailored to autonomous vehicles. Insurers leverage telematics data, AV simulation platforms, and behavioral AI to assess risk and create customized policies for robo-taxi fleets. Regulatory flexibility at the state level allows for experimentation with alternative insurance models, including usage-based pricing and fleet-level coverage. This proactive adaptation by U.S. insurers reduces one of the major commercial barriers to robo-taxi scalability and creates a more secure environment for investment and fleet expansion.U.S. Robo Taxi Market Report SegmentationThis report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the U.S. robo taxi market report based on propulsion type, component type, level of autonomy, vehicle type, service type, and application. Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary 2.1. Market Outlook2.2. Segment Outlook2.3. Competitive InsightsChapter 3. U.S. Robo Taxi Market Variables, Trends, & Scope 3.1. Market Lineage Outlook3.2. Market Dynamics3.3. U.S. Robo Taxi Market Analysis Tools3.3.1. Industry Analysis - Porter's3.3.2. PESTEL AnalysisChapter 4. U.S. Robo Taxi Market: Propulsion Type Estimates & Trend Analysis 4.1. Segment Dashboard4.2. U.S. Robo Taxi Market: Propulsion Type Movement Analysis, 2024 & 2030 (USD Million)4.3. Electric Vehicles4.4. Hybrid Electric Vehicles4.5. Fuel Cell VehiclesChapter 5. U.S. Robo Taxi Market: Component Type Estimates & Trend Analysis 5.1. Segment Dashboard5.2. U.S. Robo Taxi Market: Component Type Movement Analysis, 2024 & 2030 (USD Million)5.3. LiDAR5.4. Radar5.5. Camera5.6. SensorsChapter 6. U.S. Robo Taxi Market: Level of Autonomy Estimates & Trend Analysis 6.1. Segment Dashboard6.2. U.S. Robo Taxi Market: Level of Autonomy Movement Analysis, 2024 & 2030 (USD Million)6.3. Level 46.4. Level 5Chapter 7. U.S. Robo Taxi Market: Vehicle Type Estimates & Trend Analysis 7.1. Segment Dashboard7.2. U.S. Robo Taxi Market: Vehicle Type Movement Analysis, 2024 & 2030 (USD Million)7.3. Cars7.4. Shuttles/VansChapter 8. U.S. Robo Taxi Market: Service Type Estimates & Trend Analysis 8.1. Segment Dashboard8.2. U.S. Robo Taxi Market: Service Type Movement Analysis, 2024 & 2030 (USD Million)8.3. Car Rental8.4. Shuttles/VansChapter 9. U.S. Robo Taxi Market: Application Estimates & Trend Analysis 9.1. Segment Dashboard9.2. U.S. Robo Taxi Market: Application Movement Analysis, 2024 & 2030 (USD Million)9.3. Passengers9.4. GoodsChapter 10. Competitive Landscape 10.1. Company Categorization10.2. Company Market Positioning10.3. Company Heat Map Analysis10.4. Company Profiles Waymo Cruise LLC Tesla Inc. Aptiv Uber Technologies Inc. Lyft, Inc. Zoox, Inc. Aurora Operations, Inc. Nuro Gatik For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
21 minutes ago
- Yahoo
QuidelOrtho Corp (QDEL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges and ...
Total Revenue: $614 million, decreased from $637 million in the prior year. Revenue Growth (excluding COVID and Donor Screening): 1% growth. Adjusted EBITDA Margin: Improved by 330 basis points to 17%. Adjusted Gross Profit Margin: 45.7%, up from 44.2% in the prior year. Adjusted Diluted EPS: $0.12, compared to a loss of $0.07 in the prior year. Net Debt: Increased by $81 million, with $152 million in cash and $390 million in borrowings. Adjusted Free Cash Flow: Negative $32 million. COVID Revenue: $9 million, decreased by 52%. Molecular Revenue Growth: 24% increase. Full-Year Revenue Guidance: $2.6 billion to $2.81 billion. Full-Year Adjusted EBITDA Guidance: $575 million to $615 million. Full-Year Adjusted Diluted EPS Guidance: $2.07 to $2.57. Warning! GuruFocus has detected 7 Warning Signs with QDEL. Release Date: August 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points QuidelOrtho Corp (NASDAQ:QDEL) reported a 1% revenue growth excluding COVID and Donor Screening, with strong performance in Labs and Immunohematology business units. The company achieved a 330 basis point improvement in adjusted EBITDA margin, reflecting successful cost structure actions. QuidelOrtho Corp (NASDAQ:QDEL) saw significant growth in international markets, with Latin America, Japan, Asia Pacific, and EMEA regions showing strong performance. The company is optimistic about its molecular strategy, particularly the acquisition of LEX Diagnostics, which is expected to enhance its growth potential. QuidelOrtho Corp (NASDAQ:QDEL) earned first place rankings by ServiceTrac for best overall clinical chemistry and integrated system performance, highlighting its customer-focused approach. Negative Points North America revenue declined by 12% during the quarter, attributed to seasonally low viral prevalence. COVID-related revenue decreased significantly, impacting overall revenue figures and leading to a revised full-year COVID revenue guidance. The company is facing potential tariff headwinds estimated at $20 million to $25 million for 2025, although this is lower than previous estimates. The Donor Screening business is being wound down, contributing to a decrease in total revenue. QuidelOrtho Corp (NASDAQ:QDEL) experienced a decrease in Point of Care revenue by 21%, primarily due to lower COVID sales. Q & A Highlights Q: Can you walk through your respiratory expectations for the remainder of the year and how you arrived at your current COVID guidance? A: Joseph Busky, CFO: We are not changing our flu assumptions; the guidance remains the same. The only change is in our COVID revenue guidance. We are seeing a rise in COVID positivity, but lower ED visits and hospitalizations suggest less disease severity and likely less testing. We expect higher COVID revenue in the second half but have adjusted our full-year COVID revenue guidance to $70 million to $100 million, down from $110 million to $140 million. Q: Can you discuss the visibility and potential risks in your China revenue growth forecast? A: Brian Blaser, CEO: Our business in China is primarily clinical chemistry, where we have good pricing due to our dry-slide technology. We are underpenetrated in immunoassays, which presents an opportunity. Despite some pricing and volume actions in the market, these have had minimal impact on us. We expect higher growth in the second half, leading to mid-single-digit growth for the full year. Q: Can you explain the moving pieces affecting EBITDA, particularly with the discontinuation of Savanna and tariff impacts? A: Joseph Busky, CFO: The COVID revenue range is reduced by $40 million, impacting gross profit and adjusted EBITDA by $20 million to $25 million. This is offset by reduced tariff impacts of $15 million to $20 million and $5 million to $10 million from the Savanna discontinuation. These factors net out, keeping our adjusted EBITDA and EPS guidance unchanged. Q: What is the strategy for the molecular portfolio with the potential acquisition of LEX Diagnostics? A: Brian Blaser, CEO: The LEX platform offers ultra-fast real-time PCR results and a competitive value proposition. We plan to use both the current Sofia channel and the legacy Ortho commercial team for placements. We aim to expand the test menu beyond respiratory to areas like women's health and STI, with placements expected to scale quickly post-approval. Q: How are you planning for free cash flow in the second half of the year? A: Joseph Busky, CFO: We expect to generate $140 million to $160 million in free cash flow in the second half, aligning with our target of 25% to 30% of adjusted EBITDA. This is based on the seasonality of our business and historical performance, with more cash flow expected in the latter half of the year. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
21 minutes ago
- Yahoo
Moderna Stock: Is Wall Street Bullish or Bearish?
With a market cap of $10.7 billion, Moderna, Inc. (MRNA) is a biotechnology company specializing in the development of messenger RNA (mRNA) medicines. The company offers a broad pipeline that includes respiratory and latent virus vaccines, oncology therapeutics, and rare disease treatments, and has strategic collaborations with major global partners. Shares of the Cambridge, Massachusetts-based company have significantly underperformed the broader market over the past 52 weeks. MRNA stock has tumbled 67.2% over this time frame, while the broader S&P 500 Index ($SPX) has gained 21.5%. Moreover, Moderna's shares have plunged 33.9% on a YTD basis, compared to SPX's 7.1% rise. More News from Barchart Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? This High-Yield Dividend Stock Is Staging a Comeback. Should You Buy Shares Now? Palantir's Free Cash Flow Margins and Forecasts Rise - Where This Leaves PLTR Stock Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Looking closer, the biotechnology company stock has also lagged behind the Health Care Select Sector SPDR Fund's (XLV) 9.8% decrease over the past 52 weeks. Despite reporting a better-than-expected Q2 2025 loss of $2.13 per share and revenue of $142 million, Moderna shares dipped 6.6% on Aug. 1 due to trimmed 2025 revenue guidance of $1.5 billion - $2.2 billion. The revision stemmed from deferred UK COVID vaccine deliveries and highlighted broader concerns, including a 41% year-over-year revenue drop, slumping COVID demand, slower-than-expected RSV rollout, and regulatory delays. Additionally, the company faces mounting pressure to cut costs, targeting a $400 million reduction in 2025, after pandemic-era profits faded. For the fiscal year ending in December 2025, analysts expect Moderna's loss per share to decline 13.6% year-over-year to $10.08. However, the company's earnings surprise history is promising. It topped the consensus estimates in the last four quarters. Among the 26 analysts covering the stock, the consensus rating is a 'Hold.' That's based on three 'Strong Buy' ratings, 19 'Holds,' one 'Moderate Sell,' and three 'Strong Sells.' On Aug. 4, BofA analyst Tim Anderson lowered Moderna's price target to $24 and maintained an 'Underperform' rating. As of writing, the stock is trading below the mean price target of $42.71. The Street-high price target of $198 implies a significant potential upside from the current price levels. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
